Jade Biosciences, Inc.
NASDAQ:JBIOBiotechnology
Healthcare
$15.49 -1.25%
-$0.21 today
- Market cap
- $1.07B
- Beta
- 1.45
- P/E (TTM)
- -7.4
- EPS (TTM)
- -$2.24
52W Low $6.67High $28.00
Volume 0.79M
Average 0.83M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$113.54M
FY 2025 · Annual
Net Income
-$127.41M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 15K | 68K | 96K | 282K | 0 |
| Gross Profit | (15K) | (68K) | (96K) | (282K) | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 14.99M | 38.62M | 64.22M | 53.19M | 93.12M |
| Selling, General & Admin | 8.02M | 14.55M | 17.09M | 21.13M | 20.42M |
| Operating Expenses | 23.01M | 53.17M | 81.31M | 74.31M | 113.54M |
| Depreciation & Amortization | 15K | 68K | 96K | 282K | 26K |
| EBITDA | (22.95M) | (51.42M) | (75.37M) | (69.29M) | (127.33M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (23.02M) | (53.24M) | (81.41M) | (74.6M) | (113.54M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 65K | 1.83M | 5.95M | 5.04M | 7.78M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 62K | 1.75M | 5.94M | 5.02M | (13.81M) |
| Income Before Tax | (22.96M) | (51.49M) | (75.47M) | (69.57M) | (127.35M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 3K | 25K | 56K | 55K | 58K |
| Net Income | (22.96M) | (51.51M) | (75.52M) | (69.63M) | (127.41M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (32.96) | (73.67) | (100.38) | (85.26) | (4.06) |
| EPS (Diluted) | (32.96) | (73.67) | (100.38) | (85.26) | (4.06) |
| 697.44K | 699.2K | 752.33K | 816.63K | 31.36M | |
| 697.44K | 699.2K | 752.33K | 816.63K | 31.36M |
JBIO Earnings Waterfall · TTM
NASDAQ:JBIO · Revenue to Net Income
Key Ratios
EPS$-3.12
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-4.8
P/S Ratio0.0
Analysis
$0 of revenue converted into -$129.6M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-3.12, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 13, 2026 | |
| 10-Q | Quarterly report | Nov 13, 2026 | |
| SC 13G | SC 13G filing | Oct 28, 2026 | |
| SC 13G | SC 13G filing | Oct 27, 2026 | |
| 424B5 | 424B5 filing | Jun 3, 2026 |
How much revenue does JBIO generate?
Jade Biosciences, Inc. (JBIO) reported $0.00 of revenue in fiscal 2025.
Is JBIO profitable?
Jade Biosciences, Inc. (JBIO) reported -$127.41M of net income.
Continue the stock analysis
Jump to another research area for this company.